ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0819

The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar
Abstract Number: 0820

High Remission Rates in RA – Real Life Data from Bariticinib
Abstract Number: 0821

Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry
Abstract Number: 0822

Effectiveness After Transition to SB4 (Brenzys, Etanercept Biosimilar) versus Continuation of Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity: A Prospective Multinational Multicenter Observational Study
Abstract Number: 0823

Identifying Physician-Perceived Barriers to a Pragmatic Treatment Trial in Rheumatoid Arthritis
Abstract Number: 0824

The Comparative Effectiveness of Abatacept versus Tofacitinib After 6 Months of Treatment in Patients with RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results from a US National Observational Study
Abstract Number: 0825

Sex Differences in the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis Patients: A Post Hoc Analysis of Phase 3 and Long-Term Extension Trials
Abstract Number: 0826

Clinical Responses and Patient Flow over 2 Years of Treatment with Abatacept, Including Dose De-Escalation, in Patients with Early, MTX-Naïve, ACPA+ RA: Results from a Phase IIIb Study
Abstract Number: 0827

Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
Abstract Number: 0828

Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study
Abstract Number: 0829

International Comparison of Japanese and US Cross Country Utilization of RA Medications
Abstract Number: 0830

Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Abstract Number: 0831

Sociodemographic, Disease, and Medication Profile of RA Patients Under 65 Years Compared with 65 Years or Older at Registry Enrollment: Real World Results from a Rheumatoid Arthritis Cohort
Abstract Number: 0832

PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany
Abstract Number: 0833

Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].